Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment

Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount import...

Full description

Saved in:
Bibliographic Details
Published inBMC medical genomics Vol. 16; no. 1; p. 295
Main Authors Pu, Jingjing, Liu, Ting, Sharma, Amit, Schmidt-Wolf, Ingo G H
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 17.11.2023
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount importance to understand the complex regulatory web of mutual interactions involving epigenetic machinery and non-coding genome in regulating gene expression, herein, we investigated the intriguing interactions between HDAC6-induced lncRNA (LINC00152) and its possible sponge miRNA (hsa-miR-499a-5p) in multiple myeloma.
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:1755-8794
1755-8794
DOI:10.1186/s12920-023-01724-3